SCHEMBL858869

SCHEMBL858869

CCC(CNS(=O)(=O)c1cc(Br)cnc1N)NC(=O)OC(C)(C)C

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 4/20 0.47
GAA P10253 2/20 0.47
KDM4E B2RXH2 2/20 0.46
KMT2A Q03164 7/20 0.46
MEN1 O00255 6/20 0.46
SHMT2 P34897 1/20 0.45
PLA2G1B P04054 1/20 0.45
ATG4B Q9Y4P1 1/20 0.45
NPC1 O15118 1/20 0.45
MAPT P10636 2/20 0.43
RAB9A P51151 1/20 0.43
NPY1R P25929 1/20 0.42
NPY2R P49146 1/20 0.42
LMNA P02545 1/20 0.42
GFER P55789 1/20 0.42
ALDH1A1 P00352 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL858360 0.82 KMT2A (0.46) HSD17B10GAAKDM4EKMT2AMEN1
SCHEMBL857160 0.82 KMT2A (0.53) HSD17B10GAAKDM4EKMT2AMEN1
SCHEMBL27851856 0.80 HSD17B10 (0.46) HSD17B10GAAKDM4EKMT2AMEN1
SCHEMBL27851741 0.80 HSD17B10 (0.46) HSD17B10GAAKDM4EKMT2AMEN1
SCHEMBL856285 0.80 HSD17B10 (0.53) HSD17B10GAAKMT2AMEN1PLA2G1B
SCHEMBL856622 0.78 GAA (0.52) HSD17B10GAAKDM4EKMT2AMEN1
SCHEMBL856930 0.77 HSD17B10 (0.51) HSD17B10GAAKDM4EKMT2AMEN1
SCHEMBL27851853 0.76 KMT2A (0.46) HSD17B10GAAKDM4EKMT2AMEN1
SCHEMBL27851709 0.76 KMT2A (0.46) HSD17B10GAAKDM4EKMT2AMEN1
SCHEMBL3762844 0.76 HSD17B10 (0.47) HSD17B10GAAKDM4EKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140107100-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-04-17 US disclosed
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-03-20 US disclosed
US-8648066-B2 Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture EXELIXIS, INC. (US) 2014-02-11 US disclosed
EP-2640366-A2 BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE Exelixis, Inc. (US) 2013-09-25 EP disclosed
WO-2012068096-A2 BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE EXELIXIS, INC. (US) 2012-05-24 WO disclosed
EP-2432779-A1 BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES Exelixis, Inc. (US) 2012-03-28 EP disclosed
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2010-11-25 US disclosed
WO-2010135524-A1 BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES EXELIXIS, INC. (US) 2010-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA HSD17B10 1254/4885GAA 752/4885KDM4E 610/4885
US-20140107100-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA HSD17B10 711/4885GAA 915/4885KDM4E 361/4885
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA HSD17B10 1066/4885GAA 686/4885KDM4E 760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.